Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients

Takashi Saika, Nobuyuki Kusaka, Tomoyasu Tsushima, Toyoko Yamato, Teruhisa Ohashi, Bunzo Suyama, Ryoji Arata, Yasutomo Nasu, Hiromi Kumon

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen-independent prostate cancer, a prospective study was conducted using prostate-specific antigen (PSA) as a primary end-point. Methods: Nineteen Japanese men with stage D2 androgen-independent prostate cancer were registered and treatment was started. After ruling out anti-androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications. Results: Prostate-specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2-27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection. Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen-independent prostate cancer.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalInternational Journal of Urology
Volume8
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Dexamethasone
Androgens
Prostatic Neoplasms
Prospective Studies
Prostate-Specific Antigen
Therapeutics
Disease Progression
Bone and Bones
Treatment Failure
Survival Rate
Pain
Lung
Infection

Keywords

  • Androgen-independent prostate cancer
  • Dexamethasone

ASJC Scopus subject areas

  • Urology

Cite this

Treatment of androgen-independent prostate cancer with dexamethasone : A prospective study in stage D2 patients. / Saika, Takashi; Kusaka, Nobuyuki; Tsushima, Tomoyasu; Yamato, Toyoko; Ohashi, Teruhisa; Suyama, Bunzo; Arata, Ryoji; Nasu, Yasutomo; Kumon, Hiromi.

In: International Journal of Urology, Vol. 8, No. 6, 2001, p. 290-294.

Research output: Contribution to journalArticle

Saika, Takashi ; Kusaka, Nobuyuki ; Tsushima, Tomoyasu ; Yamato, Toyoko ; Ohashi, Teruhisa ; Suyama, Bunzo ; Arata, Ryoji ; Nasu, Yasutomo ; Kumon, Hiromi. / Treatment of androgen-independent prostate cancer with dexamethasone : A prospective study in stage D2 patients. In: International Journal of Urology. 2001 ; Vol. 8, No. 6. pp. 290-294.
@article{037c27d7d5b6450994321f2c8310e145,
title = "Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients",
abstract = "Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen-independent prostate cancer, a prospective study was conducted using prostate-specific antigen (PSA) as a primary end-point. Methods: Nineteen Japanese men with stage D2 androgen-independent prostate cancer were registered and treatment was started. After ruling out anti-androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications. Results: Prostate-specific antigen levels decreased in nine patients (50.0{\%}); five (27.8{\%}) showed a 50{\%} or greater decrease and two (11.1{\%}) showed an 80{\%} or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2-27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8{\%}). Of nine patients who had serial radiographic examinations with bone scan, three (33{\%}) showed partial response, two (22{\%}) were stable and four (44{\%}) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection. Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen-independent prostate cancer.",
keywords = "Androgen-independent prostate cancer, Dexamethasone",
author = "Takashi Saika and Nobuyuki Kusaka and Tomoyasu Tsushima and Toyoko Yamato and Teruhisa Ohashi and Bunzo Suyama and Ryoji Arata and Yasutomo Nasu and Hiromi Kumon",
year = "2001",
doi = "10.1046/j.1442-2042.2001.00302.x",
language = "English",
volume = "8",
pages = "290--294",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Treatment of androgen-independent prostate cancer with dexamethasone

T2 - A prospective study in stage D2 patients

AU - Saika, Takashi

AU - Kusaka, Nobuyuki

AU - Tsushima, Tomoyasu

AU - Yamato, Toyoko

AU - Ohashi, Teruhisa

AU - Suyama, Bunzo

AU - Arata, Ryoji

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

PY - 2001

Y1 - 2001

N2 - Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen-independent prostate cancer, a prospective study was conducted using prostate-specific antigen (PSA) as a primary end-point. Methods: Nineteen Japanese men with stage D2 androgen-independent prostate cancer were registered and treatment was started. After ruling out anti-androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications. Results: Prostate-specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2-27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection. Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen-independent prostate cancer.

AB - Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen-independent prostate cancer, a prospective study was conducted using prostate-specific antigen (PSA) as a primary end-point. Methods: Nineteen Japanese men with stage D2 androgen-independent prostate cancer were registered and treatment was started. After ruling out anti-androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications. Results: Prostate-specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2-27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection. Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen-independent prostate cancer.

KW - Androgen-independent prostate cancer

KW - Dexamethasone

UR - http://www.scopus.com/inward/record.url?scp=0034839222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034839222&partnerID=8YFLogxK

U2 - 10.1046/j.1442-2042.2001.00302.x

DO - 10.1046/j.1442-2042.2001.00302.x

M3 - Article

C2 - 11389744

AN - SCOPUS:0034839222

VL - 8

SP - 290

EP - 294

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 6

ER -